ZNF300 and neoplasm: Several limitations exist in this study; firstly, since the collection of tumour specimens from patients who present the chemoresistant phenotype is difficult, the current research could not provide the clinical evidence of the ZNF300 association with cisplatin‐induced chemoresistance.